Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DV281 |
| Synonyms | |
| Therapy Description |
DV281 is a TLR9 agonist, which may stimulate cytotoxic T-lymphocytes to enhance the immune anti-tumor response (PMID: 30502651). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DV281 | DV-281|DV 281 | TLR9 Agonist 9 | DV281 is a TLR9 agonist, which may stimulate cytotoxic T-lymphocytes to enhance the immune anti-tumor response (PMID: 30502651). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03326752 | Phase I | DV281 | Phase 1b Dose Escalation and Dose Expansion Trial | Completed | USA | 0 |